Variability in Hemodynamic Evaluation of Pulmonary Hypertension at Large Referral Centers

Despite consensus guidelines for right heart catheterization (RHC) in the diagnosis of pulmonary arterial hypertension (PAH), considerable differences exist in the performance of RHC, interpretation of hemodynamic data, and frequency of RHC performance in patients with established disease. These differences may lead to variability in diagnosis or treatment of PAH. We sought to gather information on the standard practice of RHC for the diagnosis and management of PAH from experienced pulmonary vascular disease specialists. We developed a semiquantitative online survey of diagnosis and treatment patterns of pulmonary hypertension and distributed it to physicians at pulmonary hypertension centers in the United States. Thirty of 50 physicians completed the survey: 20 pulmonologists and 10 cardiologists, all of whom reported treating >100 patients with PAH in the past year. All respondents perform RHC in ≥90% of patients with suspected PAH. All physicians determine the pulmonary wedge pressure at end expiration; however, only half of respondents personally review tracings. Physicians differed in frequency of vasodilator testing (8 of 24 performed testing in >90% of patients with PAH), fluid challenge and exercise (19 of 30 performed testing in <25% of patients with PAH for both). Most physicians (70%) report repeating RHC between 6 months and 1 year after PAH treatment initiation. Variability exists in the interpretation of hemodynamic tracings and performance of vasodilator, fluid, and exercise challenges in the management of PAH by experienced physicians in the United States. Additional consensus guidelines delineating appropriate adjunctive testing to standardize the diagnosis of PAH are needed.

[1]  D. Badesch,et al.  [Definitions and diagnosis of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[2]  J. Newman,et al.  High Prevalence of Occult Pulmonary Venous Hypertension Revealed by Fluid Challenge in Pulmonary Hypertension , 2014, Circulation. Heart failure.

[3]  B. Levine,et al.  Hemodynamic Responses to Rapid Saline Loading: The Impact of Age, Sex, and Heart Failure , 2013, Circulation.

[4]  M. Hudson,et al.  High prevalence of occult left heart disease in scleroderma-pulmonary hypertension , 2012, European Respiratory Journal.

[5]  R. Benza,et al.  World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  Gene Kim,et al.  Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. , 2012, American heart journal.

[7]  C. Mélot,et al.  Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy , 2010, Heart.

[8]  S. Halpern,et al.  Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. , 2009, Chest.

[9]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[10]  A Berghold,et al.  Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review , 2009, European Respiratory Journal.

[11]  P. Corris,et al.  Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. , 2009, American journal of respiratory and critical care medicine.

[12]  G. Raskob,et al.  Design of the REVEAL registry for US patients with pulmonary arterial hypertension. , 2008, Mayo Clinic proceedings.

[13]  J. L. Valera,et al.  Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  Eric W. Glissmeyer,et al.  Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension , 2006, Circulation.

[15]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[16]  F. Van de Werf,et al.  Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. , 2004, European heart journal.

[17]  R. Shapiro,et al.  Overestimation of pulmonary artery occlusion pressure in pulmonary hypertension due to partial occlusion , 2003, Critical care medicine.

[18]  R. Simms,et al.  Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). , 1999, Arthritis and rheumatism.

[19]  M. Humbert,et al.  Primary pulmonary hypertension associated with the use of fenfluramine derivatives. , 1998, Chest.

[20]  P. Shah,et al.  ACC expert consensus document. Present use of bedside right heart catheterization in patients with cardiac disease. American College of Cardiology. , 1998, Journal of the American College of Cardiology.

[21]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[22]  B. Brundage,et al.  The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. , 1985, Circulation.

[23]  R. Gardner,et al.  Frequency of technical problems encountered in the measurement of pulmonary artery wedge pressure , 1984, Critical care medicine.

[24]  Jeffrey L. Anderson,et al.  ACCF/AHA Expert Conseusus Document , 2009 .